

eGPA and Local Inflammation Within the Ear, Nose and Throat Area

NCT06298448

Status RECRUITING
Sponsor University Medical Center Groningen
Enrollment 150 participants

Key Eligibility Criteria

Inclusion (7)

- years of age
 - able to give informed consent
 - In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan
 - In Severe asthma group: clinical diagnosis of asthma with forced expiratory volume at one second (FEV1) $< 80\%$ AND either FEV1 reversibility $> 12\%$ initial or documented positive metacholine challenge (PC20 < 8 mg/ml)
 - In eGPA group: Fulfilling the 2022 ACR/EULAR criteria for eGPA (Wechsler et al., 2017)
- ... and 2 more (see full listing online)

Exclusion (8)

- unable to give informed consent
 - Active smoking $<$ (less than) 6 months from baseline visit
 - Concomitant use of dupilumab within 6 months of baseline visit
 - pregnant or breastfeeding woman
 - in CRSwNP group: current use of asthma medication, eGPA
- ... and 3 more (see full listing online)

Locations (1 total)

UMC Groningen, Groningen, Netherlands